Romosozumab, a monoclonal antibody that targets the protein sclerostin, has reduced the incidence of new spinal fractures in postmenopausal women with osteoporosis, according to results from a new Phase 3 study. The data were reported by UCB SA and Amgen Inc on 22 February.
